A5036413372- CAR-T cell therapy research
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Pneumocystis jirovecii pneumonia detection and treatment
- Transplantation: Methods and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Pregnancy and Medication Impact
- Infective Endocarditis Diagnosis and Management
- Inflammatory Bowel Disease
- Multiple Myeloma Research and Treatments
- Ferroptosis and cancer prognosis
- Biomedical Ethics and Regulation
- Bone and Dental Protein Studies
- Pluripotent Stem Cells Research
- Adipose Tissue and Metabolism
- Cardiac electrophysiology and arrhythmias
- Organ Transplantation Techniques and Outcomes
- Protein Degradation and Inhibitors
- Sarcoidosis and Beryllium Toxicity Research
- Ion channel regulation and function
- Radiomics and Machine Learning in Medical Imaging
- CRISPR and Genetic Engineering
- Biosimilars and Bioanalytical Methods
- Integrated Circuits and Semiconductor Failure Analysis
Center for Biologics Evaluation and Research
2018-2023
United States Food and Drug Administration
2018-2023
Ruijin Hospital
2023
Shanghai Jiao Tong University
2023
Wenzhou Hospital of Traditional Chinese Medicine
2021
Zhejiang Chinese Medical University
2021
Zhongnan Hospital of Wuhan University
2017
Wuhan University
2017
Hubei Provincial Center for Disease Control and Prevention
2017
Chinese Academy of Medical Sciences & Peking Union Medical College
2013
Abstract Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals) is a CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017, the FDA approved tisagenlecleucel for treatment of patients up to 25 years age with B-cell precursor acute lymphoblastic leukemia (ALL) that refractory in second or later relapse. Approval was based on complete remission (CR) rate, durability CR, and minimal residual disease (MRD) <0.01% cohort 63 children young adults relapsed ALL...
Abstract In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two more lines systemic therapy. Efficacy was based on complete remission (CR) rate and duration response (DOR) in 101 (median 3 prior regimens) treated single-arm trial. Patients received single infusion preceded by lymphodepleting chemotherapy...
In March 2021, the FDA approved idecabtagene vicleucel, a chimeric antigen receptor T-cell therapy targeting B-cell maturation (BCMA), for adult patients with relapsed/refractory multiple myeloma (RRMM) after ≥4 lines of including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 mAb. Approval was based on overall response rate (ORR), complete (CR) rate, duration (DOR) in 100 RRMM treated vicleucel single-arm trial. Patients received single infusion preceded by lymphodepleting...
The aim of this study is to investigate the diagnostic efficacy neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte (NMR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) in patients with Crohn’s disease (CD) non-CD controls. These ratios were all derived from complete blood counts. Two hundred six participants including CD inpatients controls retrospectively enrolled. We found statistically higher NLR PLR lower LMR than (all <mml:math...
In October 2021, the FDA approved brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Approval was based on phase II portion ZUMA-3, single-arm, open-label, multicenter trial that evaluated single infusion brexu-cel, preceded by lymphodepleting chemotherapy cyclophosphamide and fludarabine, in this population. Efficacy...
Abstract In April 2022, the FDA approved axicabtagene ciloleucel (axi-cel) for adults with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of chemoimmunotherapy. Approval was based on ZUMA-7, a randomized (1:1), open-label trial in 359 patients primary LBCL (74%) early relapse who were transplant candidates. The study compared single course axi-cel standard therapy, consisting followed by high-dose therapy and autologous...
A 22-year-old Chinese man presented with fever, cough, hoarseness, neck pain, acute heart failure and hemoptysis. Pulmonary tuberculosis was proved by sputum culture. Chest imaging showed an aortic arch pseudoaneurysm bilateral ground glass opacities. Echocardiography confirmed cardiomyopathy. With anti-TB drugs, high-dose prednisone surgery, the life of this patient successfully prolonged for more than four months. The concomitant disorders pseudoaneurysm, alveolar hemorrhage cardiomyopathy...
Abstract Background Secretory phosphoprotein 1 (SPP1) is a glyco-phosphoprotein that widely expressed in variety of cancer cells. Current studies have identified SPP1 differentially cell species. However, there are few on the level expression different types and its clinical significance. Methods In this study, we analyzed levels significance 33 by using The Cancer Genome Atlas (TCGA) database. study correlation between tumor immunity. Results results showed transcript were aberrantly most...